NCT07154706
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07154706
Title Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Acronym TRUST-IV
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Nuvation Bio Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA